Cui, Jiuwei

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., Ji, Y., Dvorkin, M., Shi, J., Pan, Z., et al. (2022) · JAMA

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 492

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2021) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 483

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., et al. (2021) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 322

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 284

Targeting T cell metabolism in the tumor microenvironment: an anti‐cancer therapeutic strategy

Yin, Z., Bai, L., Li, W., Zeng, T., Tian, H., & Cui, J. (2019) · Journal of Experimental & Clinical Cancer Research

Cancer, Hypoxia, and MetabolismCancer Immunotherapy and Biomarkers

Cited by 133

Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression

Pang, J., Shi, Q., Liu, Z., He, J., Liu, H., Lin, P., Cui, J., & Yang, J. (2017) · Haematologica

Multiple Myeloma Research and TreatmentsDrug Transport and Resistance Mechanisms

Cited by 57

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

Li, Z., Dang, X., Huang, D., Jin, S., Li, W., Shi, J., Wang, X., Zhang, Y., Song, Z., Zhang, J., et al. (2024) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 49

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis

Yang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight

Hippo pathway signaling and YAP/TAZProtein Kinase Regulation and GTPase Signaling

Cited by 31

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 23

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Shi, Y., Wu, L., Ji, Y., Chen, G., Li, B., Bi, M., Yang, R., Miao, L., Zhang, G., Gao, H., et al. (2025) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 16